Table 1 MHRA-approved anti-PD-1 and anti-PD-L1 antibodies.
Antibody | Brand name | Approval date | Target | Type | Indication | Company |
|---|---|---|---|---|---|---|
Pembrolizumab | Keytruda | 2014 | PD-1 | Humanised | Melanoma NSCLC Urothelial carcinoma Classical Hodgkin lymphoma Head and neck SCC Renal cell carcinoma | Merck, Darmstardt, Germany |
Nivolumab | Opdivo | 2014 | PD-1 | Human | Melanoma Renal cell carcinoma NSCLC Renal cell carcinoma Urothelial carcinoma Head and neck SCC Classical Hodgkin lymphoma | Bristol Myers Squibb, New York, United States |
Atezolizumab | Tecentriq | 2016 | PD-L1 | Humanised | Urothelial carcinoma NSCLC Small cell lung cancer Breast cancer | Genentech, South San Francisco, California, United States |
Durvalumab | Imfinzi | 2017 | PD-L1 | Human | NSCLC | AstraZeneca, Cambridge, United Kingdom |
Avelumab | Bavencio | 2017 | PD-L1 | Human | Merkel cell cancer Renal cell carcinoma | Merck, Darmstardt, Germany |
Cemiplimab | Libtayo | 2018 | PD-1 | Human | Cutaneous SCC | Regeneron, Greenburgh, New York, United States |
